Non-motor symptoms: identification and management (Q37082141)

18 August 2017

1 reference

title

Non-motor symptoms: identification and management (English)

1 reference

18 August 2017

K Ray Chaudhuri

1 reference

18 August 2017

Sharon Muzerengi

1 reference

18 August 2017

Donatella Contrafatto

series ordinal

1 reference

18 August 2017

language of work or name

1 reference

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

published in

1 reference

18 August 2017

volume

13 Suppl 3

1 reference

18 August 2017

page(s)

S450-6

1 reference

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Factors impacting on quality of life in Parkinson's disease: results from an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Non-motor symptoms of Parkinson's disease: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Depression rating scales in Parkinson's disease: critique and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Characteristics of apathy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Frontal-subcortical circuits and human behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Use of pramipexole in REM sleep behavior disorder: results from a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970048-8

7 January 2021

10.1016/S1353-8020(08)70048-8

Identifiers

DOI

1 reference

18 August 2017

1 reference